Gilead Sciences, Inc. (GILD) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Gilead Sciences reported revenue of $29.44B, up 2.4% from $28.75B the year before. Net income was $8.51B (a 28.9% net margin), or $6.78 per diluted share. Gross margin was 78.8% and operating margin was 34.0%. Operating activities generated $10.02B of cash, leaving $9.46B of free cash flow. At fiscal year end, Gilead Sciences held $59.02B in total assets against $36.32B in total liabilities.
Open the full interactive Gilead Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
Gilead Sciences Key Stats
| Share Price | $147.92 |
|---|---|
| Market Cap | $183.86B |
| P/E Ratio | 21.8 |
| Dividend Yield | 2.21% |
| Revenue YoY Growth | +2.4% |
| 52-Week Range | $115.01 – $153.05 |
| Shares Outstanding | 1.24 billion (basic, 2026 Q2) |
Gilead Sciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $24.69B | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
| Cost of Goods Sold | $4.57B | $6.60B | $5.66B | $6.50B | $6.25B | $6.23B |
| Gross Profit | $20.12B | $20.70B | $21.62B | $20.62B | $22.50B | $23.21B |
| Operating Income | $4.07B | $9.92B | $7.33B | $7.61B | $1.66B | $10.02B |
| Pre-Tax Income | $1.67B | $8.28B | $5.81B | $6.86B | $690.0M | $9.80B |
| Income Tax | $1.58B | $2.08B | $1.25B | $1.25B | $211.0M | $1.29B |
| Net Income | $123.0M | $6.22B | $4.59B | $5.67B | $480.0M | $8.51B |
| Diluted EPS | $0.10 | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
Gilead Sciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $7.77B | $7.92B | $6.96B | $7.80B |
| Net Income | $3.05B | $2.18B | $2.02B | -$10.50B |
| Diluted EPS | $2.43 | $1.74 | $1.61 | -$8.45 |
Gilead Sciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.00B | $5.34B | $5.41B | — | — | — |
| Current Assets | $16.00B | $14.77B | $14.44B | $16.09B | $19.17B | $18.34B |
| Total Assets | $68.41B | $67.95B | $63.17B | $62.12B | $58.99B | $59.02B |
| Current Liabilities | $11.40B | $11.61B | $11.24B | $11.28B | $12.00B | $11.81B |
| Total Long-Term Debt | $31.40B | $26.70B | $25.23B | $24.99B | $26.71B | $24.94B |
| Total Liabilities | $50.20B | $46.88B | $41.93B | $39.29B | $39.66B | $36.32B |
| Shareholders' Equity | $18.20B | $21.07B | $21.24B | $22.83B | $19.33B | $22.70B |
Gilead Sciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $8.17B | $11.38B | $9.07B | $8.01B | $10.83B | $10.02B |
| Cash From Investing | -$14.62B | -$3.13B | -$2.47B | -$2.27B | -$3.45B | -$4.79B |
| Cash From Financing | $770.0M | -$8.88B | -$6.47B | -$5.12B | -$3.43B | -$7.75B |
| Free Cash Flow | $7.52B | $10.80B | $8.34B | $7.42B | $10.30B | $9.46B |
| Dividends Paid | $3.45B | $3.60B | $3.71B | $3.81B | $3.92B | $4.00B |
Figures from Gilead Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Gilead Sciences financials page for every line item.
Gilead Sciences Company Profile
| Ticker | GILD |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Foster City, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000882095 |
Frequently Asked Questions
What was Gilead Sciences' revenue in fiscal 2025?
Gilead Sciences (GILD) reported revenue of $29.44B for fiscal 2025.
What is Gilead Sciences' annual revenue history?
Gilead Sciences' annual revenue by fiscal year: 2020: $24.69B; 2021: $27.30B; 2022: $27.28B; 2023: $27.12B; 2024: $28.75B; 2025: $29.44B.
What was Gilead Sciences' net income in fiscal 2025?
Gilead Sciences reported net income of $8.51B for fiscal 2025.
What was Gilead Sciences' earnings per share (EPS) in fiscal 2025?
Gilead Sciences' diluted EPS was $6.78 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Gilead Sciences generate in fiscal 2025?
Gilead Sciences generated $9.46B of free cash flow in fiscal 2025.
What was Gilead Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Gilead Sciences reported revenue of $7.80B.
How much debt does Gilead Sciences have?
Gilead Sciences reported $24.94B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Gilead Sciences are outstanding?
Gilead Sciences reported a weighted average of 1.24 billion basic shares outstanding in 2026 Q2.
What is Gilead Sciences' market cap?
Based on its latest closing price, Gilead Sciences (GILD) has a market capitalization of about $183.86B.
When does Gilead Sciences' fiscal year end?
Gilead Sciences' fiscal year end, as registered with the SEC, is December 31.
Where is Gilead Sciences headquartered?
Gilead Sciences lists its business address in Foster City, California in its SEC filings.